(BPT) – The role of scientific innovation and genomic cancer testing in guiding the treatment journey:

Over the last sixty years, advancements in scientific research have driven an evolution in our perception of cancer and how it is treated. There has been a shift from a “one-size-fits-all” approach toward identifying the unique genetic makeup of each patient’s tumor.

Precision oncology allows us to identify specific genomic alterations that drive the growth and spread of a tumor and inform treatment plans. Bayer is committed to playing an active role in the journey towards individualized care, by advocating for widespread access to and educating on high-quality genomic cancer testing, commonly referred to as biomarker testing.